Decreased plasma sRAGE levels in COPD: influence of oxygen therapy
Decreased plasma sRAGE levels in COPD: influence of oxygen therapy
复制标题
DOI：
10.1111/j.1365-2362.2012.02646.x
复制
发表时间：
2012-08-01
影响因子：
5.5
通讯作者：
Reynaert, Niki L.
中科院分区：
文献类型：
--
作者：
Gopal, Poornima;Rutten, Erica P. A.;Reynaert, Niki L.
背景慢性阻塞性肺疾病（COPD）与全身炎症和氧化应激相关。Ne-（羧甲基）赖氨酸（CML）是一种晚期糖基化终产物（AGE）和可溶性诱饵受体（sRAGE），是与氧化应激和炎症有关的令人兴奋的新分子。测定血浆sRAGE和CML水平，并评估其与肺功能、长期外氧治疗（LTOT）和COPD患者血浆炎症分子水平的关系。方法采用ELISA法检测146例稳定期COPD患者和81例健康受试者的血浆sRAGE和CML水平，这些受试者来自一项更大的病例对照研究，并根据年龄、性别和吸烟包年数进行匹配。结果与对照组相比，COPD患者血浆sRAGE水平降低，血浆CML水平无显著差异。在整个组中，血浆sRAGE与FEV1和用力肺活量呈正相关，与吸烟包年负相关。在接受LTOT的患者中，血浆sRAGE水平比未接受LTOT的患者低。只有在对照组中，血浆sRAGE与CML之间存在弱相关性。sRAGE与测量的炎症标志物无关，而CML与纤维蛋白原呈负相关。结论慢性阻塞性肺病患者血浆sRAGE水平低于健康对照组，接受LTOT的患者血浆sRAGE水平更低。由于sRAGE仅在整个组中与肺功能相关，因此sRAGE可被认为是COPD的标志，但不是疾病严重程度的标志。此外，sRAGE、CML和全身性炎症之间缺乏明确的关联也是显而易见的。
Eur J Clin Invest 2012 Abstract Background Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation and oxidative stress. Ne-(carboxymethyl) lysine (CML), an advanced glycation end product (AGE) and the soluble decoy receptor, sRAGE, are exciting new molecules linked to oxidative stress and inflammation. Here the levels of plasma sRAGE and CML were determined and their variation in relation to lung function, external long-term oxygen therapy (LTOT) and plasma levels of inflammatory molecules in COPD evaluated. Methods Plasma sRAGE and CML levels were measured by ELISA in 146 patients with stable COPD and 81 healthy subjects, subgrouped from a larger casecontrol study and matched for age, gender and pack-years smoked. Results Decreased levels of plasma sRAGE and no significant difference in levels of plasma CML were found in patients with COPD in comparison with controls. In the total group, plasma sRAGE was positively associated with FEV1 and forced vital capacity and negatively with pack-years smoked. In patients receiving LTOT, levels of plasma sRAGE were lower compared with those without LTOT. Only in controls, a weak correlation was found between plasma sRAGE and CML. sRAGE did not correlate with measured inflammatory markers, whereas CML was negatively correlated with fibrinogen. Conclusion Plasma sRAGE levels are lower in patients with COPD compared with healthy control subjects, and even lower levels in patients receiving LTOT. Because sRAGE correlated with lung function only in the whole group, sRAGE can be considered a marker of COPD, but not of disease severity. A lack of clear association between sRAGE, CML and systemic inflammation is furthermore evident.